Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better?

摘要: Objective The 7-day standard triple therapy (STT) gives unacceptablly low eradication rates of Helicobacter pylori (H. pylori). We aimed to examine whether extending STT from 7 days 14 or adding a bismuth compound would result in better rates. Methods H. pylori-positive patients were assigned Group A (7-day STT; rabeprazole 20 mg twice daily, amoxicillin 1 g and clarithromycin 500 for days), B with bismuth; daily subcitrate 240 days) C (14-day days). Eradication was tested using 13 C-UBT at least 4 weeks after the completion therapy. Results total 364 recruited. In intention-to-treat analysis, 79.3% (96/121; 95% confidence interval [CI] 71.3-85.6%) STT, 81.7% (98/120; CI 73.8-87.6%) bismuth, 88.6% (109/123; 81.8-93.1%) 14-day respectively. Statistical significance achieved between treatment (P = 0.048). Conclusions Adding did not an increase rate. Extending days, however, significantly higher Nevertheless, this achieve targeted 90% rate on analysis.